Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Aptamer Group Plc
Results of 2025 Annual General Meeting
Business
Nov 27 2025
3 min read

Results of 2025 Annual General Meeting

 

27 November 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Results of 2025 Annual General Meeting

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry,  today announces that the results of voting on the resolutions put to shareholders at its Annual General Meeting (AGM) held earlier today at 11:00 am at the offices of Aptamer Group, Windmill House, Innovation Way, York, YO23 1LR, all Resolutions were duly passed.

 

Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 3 November 2025, and the full poll results will be made available on the Aptamer website later today.

 

- Ends -

 

For further information, please contact: 

 

Aptamer Group plc  

Dr Arron Tolley, Chief Executive Officer

+44 (0) 1904 217 404  

SPARK Advisory Partners Limited - Nominated Adviser    

Andrew Emmott   

+44 (0) 20 3368 3550  

Turner Pope Investments (TPI) Limited - Broker    

Andrew Thacker / Guy McDougall 

+44 (0) 20 3657 0050  

Northstar Communications Limited - Investor Relations

Sarah Hollins 

+44 (0) 113 730 3896

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/